QA: Johnson Johnson in us_pharma/2011

Table of Contents

See also this year's filing and all EDGAR filings for this company.

PDF Report 0000200406_2012_Johnson_Johnson.pdf

Logs

info Ambiguous non-comprehensive roles for statement input.sec.calculation_linkbase.expand_agg {'statement': 'operations', 'non_comprehensive_roles': {'0120 - Statement - Consolidated Statements of Earnings': 11, '0121 - Statement - Consolidated Statements of Earnings (Percentage to Sales)': 11}}

Graph

Absolute values for 0000200406, Johnson Johnson

  xvar xval
0 AssetsCurrent 47,307,000,000
1 IntangibleAssetsNetIncludingGoodwill 32,010,000,000
2 PropertyPlantAndEquipmentNet 14,553,000,000
3 remainder_Assets 9,038,000,000
4 LiabilitiesCurrent 23,072,000,000
5 LiabilitiesNoncurrent 15,723,000,000
6 remainder_Liabilities 7,534,000,000
7 CostOfGoodsAndServicesSold 0
8 SellingGeneralAndAdministrativeExpense 19,424,000,000
9 ResearchAndDevelopmentExpense 6,844,000,000
10 remainder_Expenses 22,860,000,000
11 remainder_Revenues 61,587,000,000
12 remainder_NetIncome 875,000,000
13 remainder_ComprehensiveNetIncome 0
  yvar yval
0 Assets 102,908,000,000
1 Liabilities 46,329,000,000
2 Expenses 49,128,000,000
3 Revenues 61,587,000,000
4 StockholdersEquity 56,579,000,000
5 NetIncome 13,334,000,000
6 ComprehensiveNetIncome 13,334,000,000
7 BaseVar 130,413,500,000
8 EconomicCapitalRatiobeforeLimitedLiability 1.83
9 EconomicCapitalRatio 2.91

Edgar->Model Mapping

Feature Distribution

Change over Time